Valuation : Charles River Laboratories International, Inc.

Market Cap 1.38TCr 1.19TCr 1.12TCr 1.02TCr 1.91TCr 1,30000Cr 1.91TCr 13TCr 5.11TCr 67TCr 5.17TCr 5.06TCr 2,14900Cr P/E 2026 *
77.2x
P/E 2027 * 33.1x
Enterprise Value 1.59TCr 1.37TCr 1.29TCr 1.17TCr 2.2TCr 1,50000Cr 2.2TCr 15TCr 5.9TCr 77TCr 5.96TCr 5.83TCr 2,47900Cr EV / Sales 2026 *
4.06x
EV / Sales 2027 * 3.85x
Free-Float
95.58%
Yield 2026 *
-
Yield 2027 * -

Last Transcript : Charles River Laboratories International, Inc.

Manager TitleAgeSince
Chief Executive Officer 56 05/05/2026
Director of Finance/CFO 58 06/04/2026
Chief Tech/Sci/R&D Officer 45 12/01/2026
Director TitleAgeSince
Chairman 75 01/01/2000
Director/Board Member 56 05/05/2026
Chairman 69 05/05/2026
Change 5-day change 1-year change 3-year change Capi.($)
-2.40%-10.60% - - 1.38TCr
-2.54%-2.84%-1.77%+14.33% 4.89TCr
-0.40%+1.03%+418.57%+527.30% 4.5TCr
-1.42%+2.30%+42.67%+22.37% 4.41TCr
-1.22%-2.31%+4.82%+77.49% 4.07TCr
+0.53%-1.36%+16.87%+46.82% 3.35TCr
-0.21%+9.14% - - 1.78TCr
-0.35%-1.56%+21.42%+120.75% 1.65TCr
-1.01%+0.50%+13.91%+31.83% 1.47TCr
-1.65%-1.03%+75.93%+41.12% 1.38TCr
Average -1.07%+0.53%+74.05%+110.25% 3.06TCr
Weighted average by Cap. -1.10%+0.11%+89.42%+128.98%

Financials

2026 *2027 *
Net sales 391.1Cr 336.54Cr 316.64Cr 289.25Cr 541.1Cr 37TCr 542.57Cr 3.74TCr 1.45TCr 19TCr 1.47TCr 1.44TCr 61TCr 400.08Cr 344.27Cr 323.91Cr 295.89Cr 553.52Cr 38TCr 555.03Cr 3.83TCr 1.49TCr 19TCr 1.5TCr 1.47TCr 62TCr
Net income 16Cr 14Cr 13Cr 12Cr 22Cr 1.53TCr 23Cr 155.32Cr 60Cr 786.46Cr 61Cr 60Cr 2.53TCr 43Cr 37Cr 35Cr 32Cr 59Cr 4.04TCr 59Cr 409.16Cr 158.77Cr 2.07TCr 160.6Cr 157.09Cr 6.67TCr
Net Debt 211.22Cr 181.76Cr 171.01Cr 156.22Cr 292.23Cr 20TCr 293.03Cr 2.02TCr 784.15Cr 10TCr 793.17Cr 775.87Cr 33TCr 163.07Cr 140.32Cr 132.02Cr 120.6Cr 225.61Cr 15TCr 226.23Cr 1.56TCr 605.38Cr 7.9TCr 612.34Cr 598.99Cr 25TCr
Logo Charles River Laboratories International, Inc.
Charles River Laboratories International, Inc. specializes in the development of products and services in the field of research and non-clinical drug development for pharmaceutical companies, government agencies and academic institutions. Net sales break down by activity as follows: - discovery and safety assessment services (59.8%): discovery services for the identification, screening and selection of main compounds for the development of new drug candidates, and in vivo and in vitro testing, including pharmacokinetic, bioanalytical, metabolic, toxicological and pathological studies, for the safety assessment of pharmaceutical products, medical devices, animal health products, chemical and agrochemical products and biocides; - development and sale of research models and related services (21.1%): mice, rats, immunodeficient models, rabbits, guinea pigs, hamsters, etc. The group also offers primary cells and specialized products (bioconservation products, freezing media for cell cultures, antigens, peptides, humanized mouse models, etc.) for the development and manufacture of new cell therapies ; - development of solutions used in drug manufacturing processes (19.1%): products and services for microbiological testing, in vitro testing, endotoxin testing, microbial identification, development, manufacturing of avian vaccines, etc. The group also offers contract manufacturing services for cell and gene therapies. Net sales break down by source of income between sales of services (80.9%) and sales of products (19.1%). Net sales are distributed geographically as follows: the United States (53.3%), Europe (27.5%), Canada (12.5%), Asia/Pacific (5.1%), and other (1.6%).
Employees
19,000
Trader
Investor
Global
Quality
ESG MSCI
AA
40% Discount: Identify Tomorrow's Best Investments With The Best Subscriber-Only Tools!
d
:
:
SEIZE THE OFFER!